Group 1 - Steris is expected to report a year-over-year increase in earnings, with a consensus estimate of $2.32 per share, reflecting a +14.3% change, and revenues projected at $1.36 billion, up 6.2% from the previous year [3][12] - The earnings report is anticipated to be released on August 6, and the actual results will significantly influence the stock price, depending on whether they meet or exceed expectations [2][12] - The consensus EPS estimate has been revised 0.1% higher in the last 30 days, indicating a slight positive adjustment by analysts [4] Group 2 - The Earnings ESP for Steris is -3.24%, suggesting a bearish outlook from analysts, which complicates the prediction of an earnings beat [12] - Historically, Steris has beaten consensus EPS estimates three out of the last four quarters, with a recent surprise of +5.79% in the last reported quarter [13][14] - The Zacks Rank for Steris is currently 3 (Hold), which, combined with the negative Earnings ESP, makes it challenging to predict a positive earnings surprise [12][19] Group 3 - In the broader industry context, CVRx is expected to report a loss of $0.52 per share, indicating a +20% year-over-year change, with revenues projected at $13.46 million, up 14% [18] - CVRx's consensus EPS estimate has remained unchanged over the last 30 days, but it has an Earnings ESP of -0.65%, reflecting a lower Most Accurate Estimate [19]

Company Overview - RB Global (RBA) is expected to report a year-over-year increase in earnings, with a projected EPS of $0.95, reflecting a +1.1% change, and revenues of $1.12 billion, up 2.3% from the previous year [3][12]. Earnings Expectations - The consensus outlook indicates that the stock price may rise if the actual earnings exceed expectations in the upcoming report, scheduled for August 6 [2][12]. - The company has an Earnings ESP of +2.80%, suggesting analysts have recently become more optimistic about its earnings prospects [12]. Historical Performance - In the last reported quarter, RB Global exceeded the expected EPS of $0.86 by delivering $0.89, resulting in a surprise of +3.49% [13]. - Over the past four quarters, the company has consistently beaten consensus EPS estimates [14]. Analyst Sentiment - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - Despite the positive Earnings ESP, the company currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat [12][17]. Industry Comparison - Fidelity National Information Services (FIS), a peer in the Financial Transaction Services industry, is expected to report an EPS of $1.36, with revenues projected at $2.58 billion, reflecting a 3.5% increase from the previous year [18][19]. - FIS has an Earnings ESP of +0.67% and a Zacks Rank of 2, indicating a higher likelihood of beating consensus EPS estimates [20].

Company Overview - Vir Biotechnology, Inc. (VIR) is expected to report a year-over-year increase in earnings driven by higher revenues for the quarter ended June 2025, with a consensus outlook indicating a quarterly loss of $0.72 per share, reflecting a +29.4% change from the previous year [1][3] - Revenues are anticipated to reach $7.64 million, representing a significant increase of 148.1% compared to the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 7.54% higher in the last 30 days, indicating a collective reassessment by analysts [4] - The Most Accurate Estimate for Vir Biotechnology is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -22.91%, suggesting a bearish outlook from analysts [12] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, but the predictive power is significant primarily for positive readings [9][10] - Vir Biotechnology currently holds a Zacks Rank of 3, which complicates the prediction of an earnings beat given the negative Earnings ESP [12] Historical Performance - In the last reported quarter, Vir Biotechnology was expected to post a loss of $0.83 per share but actually reported a loss of -$0.88, resulting in a surprise of -6.02% [13] - Over the past four quarters, the company has only beaten consensus EPS estimates once [14] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Beam Therapeutics Inc. (BEAM) is also expected to report a loss of $1.04 per share for the same quarter, with revenues projected at $13.79 million, up 17.2% year-over-year [18][19] - Beam Therapeutics has an Earnings ESP of -23.08% and a Zacks Rank of 4, indicating challenges in predicting an earnings beat [20]

Company Overview - TKO Group Holdings (TKO) is expected to report a year-over-year increase in earnings due to higher revenues for the quarter ended June 2025, with a consensus outlook indicating a quarterly earnings of $1.23 per share, representing a +70.8% change, and revenues expected to be $1.2 billion, up 41.3% from the previous year [1][3]. Earnings Estimates and Revisions - The consensus EPS estimate has been revised 5.69% higher over the last 30 days, reflecting a reassessment by covering analysts [4]. - The Most Accurate Estimate for TKO Group is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -48.11%, indicating a bearish outlook on the company's earnings prospects [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative Earnings ESP reading indicates the likely deviation of actual earnings from the consensus estimate, with a positive reading being a strong predictor of an earnings beat [9][10]. - TKO Group currently holds a Zacks Rank of 3, making it difficult to predict an earnings beat conclusively [12]. Historical Performance - In the last reported quarter, TKO Group had an earnings surprise of +43.75%, with actual earnings of $0.69 per share compared to an expected $0.48 [13]. - Over the last four quarters, TKO Group has beaten consensus EPS estimates two times [14]. Industry Context - In the Zacks Film and Television Production and Distribution industry, Cinemark Holdings (CNK) is expected to post earnings of $0.78 per share for the same quarter, indicating a year-over-year change of +143.8%, with revenues expected to be $947.59 million, up 29.1% [18][19].

Core Viewpoint - Aclaris Therapeutics (ACRS) is anticipated to report a year-over-year increase in earnings despite lower revenues, which could significantly influence its stock price based on actual results compared to estimates [1][2]. Financial Performance Expectations - The consensus estimate indicates Aclaris is expected to post a quarterly loss of $0.13 per share, reflecting a year-over-year change of +13.3% [3]. - Revenues are projected to be $1.55 million, representing a decline of 44% from the same quarter last year [3]. Estimate Revisions and Predictions - Over the last 30 days, the consensus EPS estimate has been revised 1.41% higher, indicating a positive reassessment by analysts [4]. - Aclaris has an Earnings ESP of +10.00%, suggesting analysts have become more optimistic about the company's earnings prospects [12]. Historical Performance and Trends - In the last reported quarter, Aclaris was expected to incur a loss of $0.17 per share but actually reported a loss of $0.12, resulting in a positive surprise of +29.41% [13]. - Over the past four quarters, Aclaris has exceeded consensus EPS estimates three times [14]. Industry Context - Another player in the Zacks Medical - Drugs industry, Zoetis (ZTS), is expected to report earnings of $1.61 per share for the same quarter, indicating a year-over-year change of +3.2% [18]. - Zoetis's revenues are expected to reach $2.4 billion, up 1.7% from the previous year [18].

Core Viewpoint - The market anticipates Adient (ADNT) to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Adient is expected to post quarterly earnings of $0.47 per share, reflecting a year-over-year increase of +46.9%, while revenues are projected to be $3.56 billion, down 4.2% from the previous year [3]. - The consensus EPS estimate has been revised 15.28% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Most Accurate Estimate for Adient is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +6.47%, suggesting a strong likelihood of beating the consensus EPS estimate [12]. - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. Historical Performance - In the last reported quarter, Adient exceeded the expected earnings of $0.36 per share by delivering $0.69, resulting in a surprise of +91.67% [13]. - Over the past four quarters, Adient has beaten consensus EPS estimates three times [14]. Industry Context - Another player in the automotive sector, LCI (LCII), is expected to report earnings of $2.22 per share for the same quarter, indicating a year-over-year decline of -7.5%, with revenues expected to be $1.08 billion, up 2.2% [18]. - LCI's consensus EPS estimate has remained unchanged, but a higher Most Accurate Estimate has led to an Earnings ESP of +4.62%, indicating a likely earnings beat [19].

Core Viewpoint - Acadia Pharmaceuticals is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended June 2025, with the actual results being crucial for its near-term stock price movement [1][2]. Financial Expectations - The consensus estimate for Acadia's quarterly earnings is $0.14 per share, reflecting a year-over-year decrease of 30%. Revenues are projected to be $260.28 million, representing a 7.6% increase from the previous year [3]. - The consensus EPS estimate has been revised down by 1.59% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Potential - Acadia's Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +17.43%, suggesting a bullish outlook from analysts [12]. - The stock holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Acadia was expected to post earnings of $0.10 per share but exceeded this with earnings of $0.11, achieving a surprise of +10.00% [13]. - Over the past four quarters, Acadia has surpassed consensus EPS estimates three times [14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, TG Therapeutics is expected to report earnings of $0.32 per share for the same quarter, indicating a year-over-year increase of 700%, with revenues projected at $136.04 million, up 85.2% from the previous year [18][19].

Core Viewpoint - The market anticipates Arcutis Biotherapeutics, Inc. (ARQT) will report a year-over-year increase in earnings driven by higher revenues when it releases its results for the quarter ended June 2025 [1] Financial Expectations - The upcoming earnings report is expected to show a quarterly loss of $0.18 per share, reflecting a year-over-year change of +57.1% [3] - Revenues are projected to be $72.57 million, representing a significant increase of 135.2% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 17.02% higher in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictive power for positive readings [9][10] - Arcutis Biotherapeutics currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12][13] Historical Performance - In the last reported quarter, Arcutis Biotherapeutics was expected to post a loss of $0.21 per share but delivered a loss of -$0.20, resulting in a surprise of +4.76% [14] - The company has beaten consensus EPS estimates in each of the last four quarters [15] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Halozyme Therapeutics (HALO) is expected to report earnings of $1.23 per share for the same quarter, indicating a year-over-year change of +35.2% [19] - Halozyme's revenue is projected to be $286.12 million, up 23.7% from the previous year, with a revised consensus EPS estimate reflecting a 1.5% increase [20]

Core Viewpoint - The market anticipates Certara, Inc. (CERT) to report a year-over-year earnings increase driven by higher revenues when it releases its quarterly results for June 2025 [1] Earnings Expectations - Certara is expected to post quarterly earnings of $0.10 per share, reflecting a year-over-year increase of +42.9% [3] - Revenues are projected to reach $103.56 million, which is an 11% increase from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate for Certara has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] - The Most Accurate Estimate for Certara is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +2.44%, suggesting a bullish outlook from analysts [12] Earnings Surprise History - In the last reported quarter, Certara exceeded the expected earnings of $0.13 per share by delivering $0.14, resulting in a surprise of +7.69% [13] - Over the past four quarters, Certara has beaten consensus EPS estimates three times [14] Industry Context - Enanta Pharmaceuticals (ENTA), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $1.25 per share for the same quarter, indicating a year-over-year decline of -16.8% [18] - Enanta's revenues are anticipated to be $15.1 million, down 16% from the previous year [19] - Despite a significant downward revision of 28.9% in the consensus EPS estimate for Enanta over the last 30 days, it currently has an Earnings ESP of +2.4% [19]

Core Viewpoint - Capri Holdings (CPRI) is expected to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2025, with the consensus outlook being crucial for assessing the company's earnings picture [1][3]. Earnings Expectations - The upcoming earnings report is anticipated to show earnings of $0.13 per share, reflecting a significant year-over-year increase of +225%, while revenues are projected to decline by 27.4% to $774.5 million [3]. - The stock price may rise if the actual earnings exceed expectations, whereas a miss could lead to a decline in stock value [2]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 3.54%, indicating a collective reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Capri Holdings is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.49%, suggesting a bearish outlook from analysts [12]. Historical Performance - Capri Holdings has not been able to beat consensus EPS estimates in the last four quarters, with a notable surprise of -2,962.50% in the last reported quarter where a loss of $0.16 per share was expected, but the actual loss was -$4.90 [13][14]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a favorable Zacks Rank [10]. - Capri Holdings currently holds a Zacks Rank of 5 (Strong Sell), which complicates the prediction of an earnings beat [12]. Conclusion - Capri Holdings does not appear to be a compelling candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [17].